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The presence of HER2 exon 20 insertion in patients with central 
nervous system metastases from non-small lung cancer  
— a potential application in classification for therapy
Obecność insercji w eksonie 20 genu HER 2 u chorych z przerzutami 
niedrobnokomórkowego raka płuca do centralnego układu nerwowego  
— potencjalne zastosowanie w kwalifikacji do terapii
The authors declare no financial disclosure.
Abstract
Introduction: HER2 (ErbB2/neu) is a member of the ErbB family of four structurally related receptors of tyrosine kinase activity. 
Overexpression of ErbB-1 (EGFR) and HER2 is found in many human cancers, but the presence of these genes mutations determi-
nes the effectiveness of EGFR and HER2 tyrosine kinase inhibitors in the therapy of non-small cell lung cancer (NSCLC). 
Material and methods: To search for insertions of the HER2 gene in exon 20 in 150 brain metastases of non-small cell lung 
cancer patients, we used a PCR technique based on analysis of amplified DNA fragment lengths. We also compared the HER2 
mutational status with clinicopathologic features and the presence of EGFR and BRAF mutations. 
Results: HER2 mutation was present in one male, non-smoking patient with low differentiated adenocarcinoma (0.67% of all patients and 
1.5% of patients with adenocarcinoma). The mutations of EGFR and BRAF genes were not found in HER2-mutated patient. 
Conclusions: The literature data suggests that patients with HER2 mutations may be sensitive to tyrosine kinase inhibitors 
of both EGFR and HER2 receptors (e.g. afatinib). Therefore, the identification of new driver mutations in NSCLC can improve 
the quality of patient care by enabling the use of correct molecularly targeted therapies.
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Streszczenie
Wstęp: HER2 (ErbB2/neu) jest białkiem należącym do rodziny receptorów HER (EGFR, HER2, HER3 i HER4), posiadających 
w swej części wewnątrzkomórkowej aktywność kinazy tyrozynowej. Nadekspresja EGFR i HER2 występuje w wielu typach 
nowotworów, ale to mutacje w genach kodujących te receptory uwrażliwiają chorych na niedrobnokomórkowego raka płuca 
(NSCLC) na działanie inhibitorów kinaz tyrozynowych EGFR i HER2. 
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Introduction
The family of HER (ErbB) receptors consists of 
four receptors: HER1 (EGFR, ErbB1), HER2 (Neu, 
ErbB2), HER3 (ErbB3) and HER4 (ErbB4), which all 
have in their intracellular part a domain of tyrosine 
kinase activity. The abbreviation ErbB comes from the 
name of a viral oncogene (erythroblastic leukaemia 
viral oncogene) that is connected with the occurrence 
of erythroblastic leukaemia, and whose structure is 
homologous with the structure of human HER recep-
tors. The signal for proliferation of epithelial cells is 
transmitted to a nucleus as a result of homo- or het-
erodimerization of HER receptors and after stimulation 
of such complexes by relevant ligands. A preferable 
partner in heterodimerization for EGFR (epidermal 
growth factor receptor) is HER2 receptor. Overex-
pression of HER2 receptor is strongly connected with 
formation of breast carcinoma. Whereas mutations in 
tyrosine kinase domain within the EGFR gene-espe-
cially deletions in exon 19 and L858R substitution in 
exon 21 of this gene — that direct bronchial epithelial 
cells to carcinogenesis occur in approximately 10% 
of Caucasian patients. Furthermore, the presence 
of EGFR mutation conditions the effectiveness of 
EGFR tyrosine kinase inhibitor (IKT EGFR). Some 
researchers also report that HER2 mutations (to 
a lesser degree high expression of this receptor) may 
be the cause for some NSCLC cases [1–5].
Mutations in HER2 tyrosine kinase domain 
are very rare in NSCLC patients. Preliminary data 
report that they concern less than 2% of the total 
population of patients. Usually they are diagnosed 
in non-smoking females with adenocarcinoma of 
the lungs. The most important mutations are two 
different insertions of twelve pairs of nucleotides 
that disturb the reading frame in exon 20 of HER2: 
A775YVMA (66% of all mutations detected in the 
HER2 gene) or M774AYVM. These mutations are ana-
logous with the insertion of nine base pairs in exon 20 
of the EGFR that makes the structure of HER2 tyrosine 
kinase domain resemble the structure of EGFR tyro-
sine kinase domain, which has been modified by the 
Materiał i metody: Wykorzystano technikę PCR oraz analizę długości fragmentów amplifikowanego DNA w celu zidentyfiko-
wania u 150 chorych insercji 12 par zasad w obrębie eksonu 20 genu HER2 w przerzutach NDRP do mózgu. 
Wyniki: W guzie z wykrytą mutacją HER2 nie stwierdzono mutacji EGFR ani BRAF. Insercja w eksonie 20 genu HER2 została 
wykryta u 77-letniego niepalącego mężczyzny chorego na niskozróżnicowanego raka gruczołowego (0,67% wszystkich cho-
rych oraz 1,5% chorych na raka gruczołowego). U tego chorego nie zidentyfikowano innych nieprawidłowości genetycznych. 
Wnioski: W literaturze opisano, że u chorych posiadających mutację w genie HER2 mogą okazać się skuteczne inhibitory specy-
ficzne w stosunku do kinaz tyrozynowych obu receptorów: EGFR i HER2 (np. afatynib). Dlatego też identyfikacja nowych mutacji 
kierujących w komórkach NSCLC wydaje się kluczem do właściwej kwalifikacji do terapii ukierunkowanych molekularnie.
Słowa kluczowe: niedrobnokomórkowy rak płuca, przerzuty do mózgu, mutacja HER2
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mentioned mutations. Therefore, it is assumed that 
mutations A775YVMA or M774AYVM of the HER2 
gene result in similar consequences as mutations 
in exon 20 of the EGFR gene. Taking into account 
that HER2 receptor heterodimerizes in a preferential 
way with receptor for EGF, the structure of the ATP 
binding pocket, which is caused by mutation in exon 
20 of the EGFR or HER2 gene in heterodimer EGFR/ 
/HER2, leads to the growth of tyrosine kinase ac-
tivity of these receptors. This results in excessi-
ve phosphorylation of subsequent signal peptides, 
proliferation of neoplastic cells, and resistance 
(or smaller sensitivity) to the action of reversible 
IKT EGFR [4, 6–11].
The presence of mutations A775YVMA or 
M774AYVM in the HER2 gene may, in future, be 
a potential predictive marker of successful IKT 
EGFR therapy, and it may also become the goal for 
new molecularly targeted therapies. The investi-
gation of insertion in exon 20 of the HER2 may be 
as crucial for therapy planning as the evaluation 
of the presence of T790M mutation in the EGFR 
gene, which currently seems to be the main cause 
for resistance to IKT EGFR (50% of resistance ca-
ses). It should be remembered that many patients 
start IKT EGFR therapy when they are at advanced 
stage of NSCLC, and brain metastases are the most 
frequent place of metastases from adenocarcinoma 
of the lungs. Unfortunately, we know little about 
the frequency of occurrence of mutations in the 
HER2 gene in metastatic tumours from NSCLC 
and in patients with pathomorphological diagnosis 
other than adenocarcinoma.
Material and methods
The research included retrospectively 150 
patients (102 males and 48 females) from 38 to 81 
years of age (59.8 ± 8.8 years), whose paraffin ma-
terial of neoplastic tissue collected from metastatic 
foci in the central nervous system from NSCLC 
was available. The patients underwent standard 
neurosurgical operation of palliative character. 
Pneumonologia i Alergologia Polska 2013, tom 81, nr 4, strony 294–297 
296 www.pneumonologia.viamedica.pl
Thirty-two patients had available material from 
a primary tumour collected during operations, 
thoracoscopy, endobronchial or transbronchial 
biopsy, or taken through the chest wall. 
Sixty-six patients were diagnosed with ade-
nocarcinoma of the lungs (44%). Squamous cell 
carcinoma was diagnosed in 24 cases (16%), and 
giant cell carcinoma in 22 patients (15%); 38 pa-
tients (25%) were not diagnosed with any type 
of NSCLC (not otherwise specified — NOS). The 
median of the time of the patients’ life from the 
moment of diagnosis until death was 9.2 months. 
None of the patients was treated with IKT EGFR.
DNA was isolated from paraffin material, 
including neoplastic tissue of metastatic and 
primary NSCLC tumours, by using a Qiamp DNA 
FFPE tissue kit (Qiagen,USA). The evaluation of 
insertion in exon 20 of the HER2 was performed by 
using PCR assay with the help of a pair of primers 
flanking the mutated region of the HER2 gene. 
One of the primers was determined by fluorochro-
me Cy5. The analysis of the length of amplified 
DNA fragments was conducted in ALF Express II 
sequenator by using ALFWin Fragment Analyzer. 
Additionally, the presence of deletion in exon 19, 
substitution T790M, substitution L858R in the 
EGFR gene, and mutation V600E in the BRAF gene 
was studied in the investigated material.
Results
The described method appeared to be sensitive 
enough to evaluate the presence or lack of mutation 
in the HER2 gene in all examined patients (Fig. 1). 
Furthermore, analysis of the occurrence of muta-
tions in the EGFR and BRAF genes was carried out 
in the examined group. Mutations in the EGFR 
gene in 9 patients (6.29%) and no mutation in the 
BRAF gene were discovered. However, the presence 
of an insertion in exon 20 of the HER2 (insertion 
variant A775YVMA or M774AYVM) was found 
only in one patient who had available material 
from a metastatic tumour from NSCLC (0.67% of 
all examined patients and 1.5% of patients with 
diagnosis of adenocarcinoma). This mutation was 
found in a 77-year-old non-smoking male, who had 
been diagnosed with advanced low differentiated 
adenocarcinoma of the lungs with cerebellar me-
tastases. Due to his poor condition after neurosur-
gical operation, and the progression of the disease, 
the patient was not treated with chemotherapy, 
radiotherapy or other molecularly targeted therapy. 
Additional molecular examinations of the patient 
excluded the presence of activating mutations in 
exon 19, exon 20 (T790M) and exon 21 (L858R) of the 
EGFR gene or substitution V600E in the BRAF gene.
Discussion
The present study proves that primary muta-
tions in the HER2 gene may be discovered in Polish 
patients with NSCLC, not treated with molecularly 
targeted therapies. Furthermore, mutation in the 
HER2 gene has been noted in metastatic cerebellum 
tumours from NSCLC, which is the first such report 
in the world. Mutations in the HER2 gene are proba-
bly responsible for the development of the forms of 
lung cancer that do not depend on tobacco smoke 
carcinogens, especially adenocarcinoma. However, 
the occurrence of mutations in the HER2 gene in 
Caucasian patients is very rare. This research found 
it in less than 1% of NSCLC patients.
Shigematsu et al. searched for mutations in 
the HER2 gene in 671 primary NSCLC tumours 
and in 80 NSCLC cell lines and other types of 
neoplasms (140). The authors found different 
types of insertion in exon 20 of the HER2 gene in 
11 patients with NSCLC (1.6%) and in one cell line 
— adenocarcinoma of the lungs (NCI-H1781). Such 
mutation has not been discovered in other types of 
neoplasms, including 55 small cell lung cancers. 
Mutations in the HER2 gene were more frequent 
in non-smokers (3.2%, 8 out of 248 patients) 
and have occurred exclusively in patients with 
adenocarcinoma (2.8%, 11 out of 394 patients). 
Moreover, they were more often in females (2.7%, 
7 out of 258 females) than in males (1%, 4 out of 
413 males). Only one mutation was diagnosed in 
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Figure 1. Exemplary analysis of mutation in the HER2 gene. Double 
peaks on line no. 3 are evidence for the presence of two PCR pro-
ducts that differ in number of base pairs (bp): the shorter one with 
342 base pairs, typical of the wild HER2 gene, and the longer one 
(12 base pairs insertion) typical of HER2 mutant gene. A single peak of the 
size of 342 base pairs on the lines 7–9 proves solely the presence of a wild
-type HER2 gene. The experiment did not use a positive control presenting 
the result of DNA amplification with sequence with HER2 mutation due to 
lack of commercial availability of DNA with such a sequence
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Caucasian patients (0.73%, 1 out of 137 patients) 
[6]. In another study, Sasaki et al. found only one 
non-smoking patient with adenocarcinoma who 
had mutation in the form of insertion of 12 nuc-
leotides in exon 20 of the HER2 gene among the 
95 examined patients with NSCLC [7]. Buttitta et al. 
diagnosed mutation in the HER2 gene in 9 of 403 
Caucasian patients with adenocarcinoma (2.2%), 
while 7 mutations were 12-nucleotide insertion 
within exon 20. Mutations have been found more 
often in females (4.1%), non-smokers (3.1%) and 
in patients with pattern of bronchiolalveolar carci-
noma (6.2%), although they have been also found 
in males (1.8%) and in smokers (1.9%) [9].
The results of the quoted research projects and the 
present study are contradictory to the results obtained 
by Stephens et al., who declared that mutations in the 
tyrosine kinase domain in the HER2 gene (various 
types of mutations and abnormalities in the HER2 
gene) occur in 4% of NSCLC patients (120 investiga-
ted primary tumours), including 10% of patients with 
adenocarcinoma [9]. Moreover, Lee et al. described 
12 carriers of mutations in the HER2 gene in a group of 
202 non-smoking Caucasian patients (6%) who under-
went surgery due to adenocarcinoma of the lungs [11].
If we assume that mutations in the HER2 gene 
are driver mutations that direct bronchial epithelial 
cells to carcinogenesis, and that they do not coexist 
with other driver mutations (coexistence of insertion 
in exon 20 of the HER2 gene with some mutations in 
the EGFR and BRAF genes has been excluded in the 
present paper), molecularly targeted therapy directed 
against the HER2 tyrosine kinase may be sought for 
patients with this mutation. Tyrosine kinase inhibitors 
that inhibit exclusively EGFR tyrosine kinase activity 
(gefitinib and erlotinib) in the case of mutation in the 
HER2 gene are ineffective. Lapatinib — double, rever-
sible EGFR and HER2 tyrosine kinase inhibitor has 
showed activity towards cell lines but it was ineffecti-
ve in patients with non-small cell lung cancer [12, 13]. 
Whereas afatinib (BIBW 2992) — irreversible EGFR, 
HER2 and HER4 tyrosine kinase inhibitor has appe-
ared to be successful in eliminating neoplastic cells 
with HER2 mutation in both: cell cultures and animal 
models [14–18]. Moreover, there are first reports on 
cases concerning the effectiveness of this drug in fema-
les with adenocarcinoma, who were carriers of HER2 
mutation [19]. Experiments in vitro on the possible use 
of therapy combining afatinib and sirolimus (mTOR 
inhibitor) in patients with HER2 mutation are being 
conducted [4]. Additionally, trastuzumab — monoc-
lonal antibody to HER2 extracellular domain, which 
is successfully used in therapy for women with breast 
cancer and HER2 overexpression, may be effective in 
patients with NSCLC from HER2 mutation [20].
The above discussion shows that analysis of 
patients’ genetic profile may increase the range of 
possibilities for the use of molecularly targeted 
therapies in NSCLC patients. It is possible that in 
the future personalized NSCLC therapy based on 
examination of many various mutations in neopla-
stic cells will be the reality.
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